Literature DB >> 3132651

Bladder hyperreflexia induced in marmosets by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.

A Albanese1, P Jenner, C D Marsden, J D Stephenson.   

Abstract

In marmosets, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) causes degeneration of the cell bodies of the substantia nigra and the animals subsequently develop parkinsonian symptoms. Cystometrograms obtained from such animals while under pentobarbitone anaesthesia, showed their bladders to be hyperreflexic when compared to those of normal animals of the same age (less than 2 years). Bladder hyperreflexia is present in many parkinsonian patients and is difficult to treat, partly because it is made worse by dopaminergic agents. This is the first demonstration of an effect of MPTP on this type of peripheral function. It suggests the suitability of MPTP-treated marmosets for studying the mechanisms by which a loss of nigrostriatal dopamine leads to bladder hyperreflexia and for devising pharmacological strategies which may be of therapeutic value in the clinic.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3132651     DOI: 10.1016/0304-3940(88)90143-7

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  13 in total

Review 1.  CNS involvement in overactive bladder: pathophysiology and opportunities for pharmacological intervention.

Authors:  Karl-Erik Andersson; Rikard Pehrson
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 2.  Neural control of the lower urinary tract.

Authors:  William C de Groat; Derek Griffiths; Naoki Yoshimura
Journal:  Compr Physiol       Date:  2015-01       Impact factor: 9.090

Review 3.  Non-motor features of Parkinson disease.

Authors:  Anthony H V Schapira; K Ray Chaudhuri; Peter Jenner
Journal:  Nat Rev Neurosci       Date:  2017-06-08       Impact factor: 34.870

Review 4.  Non-human primate models of PD to test novel therapies.

Authors:  Marc Morissette; Thérèse Di Paolo
Journal:  J Neural Transm (Vienna)       Date:  2017-04-08       Impact factor: 3.575

5.  Dopaminergic mechanisms underlying bladder hyperactivity in rats with a unilateral 6-hydroxydopamine (6-OHDA) lesion of the nigrostriatal pathway.

Authors:  Naoki Yoshimura; Sadako Kuno; Michael B Chancellor; William C De Groat; Satoshi Seki
Journal:  Br J Pharmacol       Date:  2003-08       Impact factor: 8.739

Review 6.  Animal models in urological disease and sexual dysfunction.

Authors:  Gordon McMurray; James H Casey; Alasdair M Naylor
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 7.  Pharmacological methods for the preclinical assessment of therapeutics for OAB: an up-to-date review.

Authors:  Emilio Sacco; Riccardo Bientinesi; Pierfrancesco Bassi; Diego Currò
Journal:  Int Urogynecol J       Date:  2016-02-17       Impact factor: 2.894

Review 8.  Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease.

Authors:  Susan Duty; Peter Jenner
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

Review 9.  Treatment of the later stages of Parkinson's disease - pharmacological approaches now and in the future.

Authors:  Peter Jenner
Journal:  Transl Neurodegener       Date:  2015-02-12       Impact factor: 8.014

Review 10.  New Frontiers of Basic Science Research in Neurogenic Lower Urinary Tract Dysfunction.

Authors:  Minoru Miyazato; Katsumi Kadekawa; Takeya Kitta; Naoki Wada; Nobutaka Shimizu; William C de Groat; Lori A Birder; Anthony J Kanai; Seiichi Saito; Naoki Yoshimura
Journal:  Urol Clin North Am       Date:  2017-08       Impact factor: 2.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.